Toward novel vaccines against tuberculosis: current hopes and obstacles
- PMID: 21165340
- PMCID: PMC3002148
Toward novel vaccines against tuberculosis: current hopes and obstacles
Abstract
Approximately 2 million people die of tuberculosis (TB) each year. The current vaccine, Bacille Calmette-Guérin (BCG), albeit widely employed, does not protect against adult pulmonary disease, and new vaccines are urgently needed to reduce the incidence of TB worldwide. New insights into the cellular and molecular mechanisms that underlie the interactions between Mycobacterium tuberculosis and its host have been exploited to develop novel vaccine candidates that recently have entered clinical trials. This review provides a brief overview of different approaches toward a new vaccination strategy and summarizes major challenges for the next decade.
Keywords: BCG; global open access; tuberculosis; vaccines.
Conflict of interest statement
Conflict of interest: S.H.E. Kaufmann is co-inventor of the rBCGΔUreC:Hly vaccine candidate.
References
-
- Lönnroth K, Castro KG, Chakaya JM. et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010;375(9728):1814–1829. - PubMed
-
- Kaufmann SHE, Hussey G, Lambert P. New vaccines for tuberculosis. Lancet. 2010;375(9731):2110–2119. - PubMed
-
- Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol. 2007;5(1):39–47. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical